Danazol in refractory autoimmune thrombocytopenic purpura (ATP). A new therapeutic sequence

R Ambriz-Fernández, R Ambríz-Fernández, G Chávez-Sánchez, J Pizzuto-Chávez, Morales-Polanco Mr, M R Morales-Polanco, A Aviles-Miranda, A Avilés-Miranda
Archivos de investigacion medica · 1986 · vol. 16(3) , pp. 295–304 · PMID:3833096 · W2408764714
Other OA: closed CC0 ⤵ 1 in-corpus citation
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-13 ⓘ

This paper investigates the efficacy of danazol in a new therapeutic sequence for patients with refractory autoimmune thrombocytopenic purpura.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

MeSH descriptors

Autoimmune Diseases Danazol Pregnadienes Purpura, Thrombocytopenic Adolescent Adult Aged Autoimmune Diseases Autoimmune Diseases Autoimmune Diseases Combined Modality Therapy Danazol Female Humans Male Metrorrhagia Metrorrhagia Metrorrhagia Middle Aged Platelet Count

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Cited by (1)

Source provenance

openalex
last seen: 2026-05-10T10:46:03.109450+00:00
pubmed
last seen: 2026-10-08T21:42:56.815463+00:00
License: CC0 · commercial use OK